培美曲塞单药治疗晚期非小细胞肺癌复治患者的临床观察  

Pemetrexed alone regimen in treatment of advanced chemo-recurrent non-small cell lung cancer

作　　者：郑鸿[1] 陶莉[1] 张文[2] 

机构地区：[1]上海市复旦大学肿瘤医院闵行分院化疗科,上海200163 [2]上海市复旦大学肿瘤医院化疗科,上海200163

出　　处：《中华肿瘤防治杂志》2010年第20期1679-1680,共2页Chinese Journal of Cancer Prevention and Treatment

摘　　要：为了探讨培美曲塞单药治疗晚期复治非小细胞肺癌(NSCLC)的疗效及不良反应,经病理学或细胞学确诊的复发性晚期NSCLC患者58例,给予培美曲塞500mg/m2,d1,静脉滴入,每3周重复,2～3个周期后评价疗效及不良反应。58例患者中无完全缓解病例,部分缓解(PR)6例,稳定(SD)33例,进展19(PD)例,疾病控制率67.2%(39/58)。中位无疾病进展时间(MPFS)2.9个月。主要不良反应为粒细胞下降、贫血。初步研究结果提示,培美曲塞单药治疗一线化疗失败的晚期NCLC患者疗效确切。不良反应发生率低,耐受性较好。The objective of this study was to evaluate the efficacy and side effects of pemetrexed alone in the treatment of advanced chemo-recurrent NSCLC.Fifty-eight patients with advanced NSCLC who had failed to previous chemotherapy were enrolled in this study and all of these patients had been confirmed with pathology or cytology.The patients received pemetrexed 500 mg/m2 on day 1,by intravenous infusion,with every 21 days,and 21 days as one cycle.All the patients who received 2 or 3 cycles were evaluated.There was no case with complete response.Six cases had partial response,33 cases had stable disease and 19 cases had progressive disease.The disease control rate was 67.2%（39/58）.The median survival time was 2.9 months.The common adverse effects were leucopenia and anemia.Pemetrexed is effective and feasible for advanced recurrent NSCLC.Pemetrexed is one of the choices for NSCLC patients who fail in the first line chemotherapy.

关 键 词：培美曲塞 癌 非小细胞肺 药物疗法 治疗结果 

分 类 号：R734.2[医药卫生—肿瘤]